Nektar says rezpegaldesleukin shows early biomarker response in Phase 2b REZOLVE-AD atopic dermatitis study

By Public Technologies
  • Nektar Therapeutics disclosed new biomarker results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin in moderate-to-severe atopic dermatitis.
  • Findings were presented in a late-breaking oral session at the EADV Congress 2026.
  • Data showed early biological activity consistent with the drug’s regulatory T-cell mechanism, with changes emerging within the first weeks of dosing.
  • Early molecular shifts tracked with later clinical improvement in treated patients, supporting rezpegaldesleukin’s positioning as a broader immune-modulating approach.
  • Results underpin the company’s plan to advance the program into Phase 3 development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609301030PR_NEWS_USPR_____SF59259) on September 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.